220 related articles for article (PubMed ID: 34342224)
1. Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.
McKinney DC; McMillan BJ; Ranaghan MJ; Moroco JA; Brousseau M; Mullin-Bernstein Z; O'Keefe M; McCarren P; Mesleh MF; Mulvaney KM; Robinson F; Singh R; Bajrami B; Wagner FF; Hilgraf R; Drysdale MJ; Campbell AJ; Skepner A; Timm DE; Porter D; Kaushik VK; Sellers WR; Ianari A
J Med Chem; 2021 Aug; 64(15):11148-11168. PubMed ID: 34342224
[TBL] [Abstract][Full Text] [Related]
2. Development of Macrocyclic PRMT5-Adaptor Protein Interaction Inhibitors.
Krzyzanowski A; Esser LM; Willaume A; Prudent R; Peter C; 't Hart P; Waldmann H
J Med Chem; 2022 Nov; 65(22):15300-15311. PubMed ID: 36378254
[TBL] [Abstract][Full Text] [Related]
3. RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5), competes with pICln for binding and modulates PRMT5 complex composition and substrate specificity.
Guderian G; Peter C; Wiesner J; Sickmann A; Schulze-Osthoff K; Fischer U; Grimmler M
J Biol Chem; 2011 Jan; 286(3):1976-86. PubMed ID: 21081503
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for substrate recruitment to the PRMT5 methylosome.
Mulvaney KM; Blomquist C; Acharya N; Li R; Ranaghan MJ; O'Keefe M; Rodriguez DJ; Young MJ; Kesar D; Pal D; Stokes M; Nelson AJ; Jain SS; Yang A; Mullin-Bernstein Z; Columbus J; Bozal FK; Skepner A; Raymond D; LaRussa S; McKinney DC; Freyzon Y; Baidi Y; Porter D; Aguirre AJ; Ianari A; McMillan B; Sellers WR
Mol Cell; 2021 Sep; 81(17):3481-3495.e7. PubMed ID: 34358446
[TBL] [Abstract][Full Text] [Related]
5. Biochemical Investigation of the Interaction of pICln, RioK1 and COPR5 with the PRMT5-MEP50 Complex.
Krzyzanowski A; Gasper R; Adihou H; Hart P'; Waldmann H
Chembiochem; 2021 Jun; 22(11):1908-1914. PubMed ID: 33624332
[TBL] [Abstract][Full Text] [Related]
6. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.
Stopa N; Krebs JE; Shechter D
Cell Mol Life Sci; 2015 Jun; 72(11):2041-59. PubMed ID: 25662273
[TBL] [Abstract][Full Text] [Related]
7. Histone H2A and H4 N-terminal tails are positioned by the MEP50 WD repeat protein for efficient methylation by the PRMT5 arginine methyltransferase.
Burgos ES; Wilczek C; Onikubo T; Bonanno JB; Jansong J; Reimer U; Shechter D
J Biol Chem; 2015 Apr; 290(15):9674-89. PubMed ID: 25713080
[TBL] [Abstract][Full Text] [Related]
8. Interaction assessments of the first S-adenosylmethionine competitive inhibitor and the essential interacting partner methylosome protein 50 with protein arginine methyltransferase 5 by combined computational methods.
Zhu K; Jiang CS; Hu J; Liu X; Yan X; Tao H; Luo C; Zhang H
Biochem Biophys Res Commun; 2018 Jan; 495(1):721-727. PubMed ID: 29154828
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Biological Characterization of PRMT5:MEP50 Protein-Protein Interaction Inhibitors.
Asberry AM; Cai X; Deng X; Santiago U; Liu S; Sims HS; Liang W; Xu X; Wan J; Jiang W; Camacho CJ; Dai M; Hu CD
J Med Chem; 2022 Oct; 65(20):13793-13812. PubMed ID: 36206451
[TBL] [Abstract][Full Text] [Related]
10. NF90/NFAR (nuclear factors associated with dsRNA) - a new methylation substrate of the PRMT5-WD45-RioK1 complex.
Cox J; Esser LM; Jüdt M; Schmitz K; Reiffert K; Grimmler M; Stork B; Wesselborg S; Peter C
Biol Chem; 2022 Sep; 403(10):907-915. PubMed ID: 36040368
[TBL] [Abstract][Full Text] [Related]
11. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
Zhu K; Jiang C; Tao H; Liu J; Zhang H; Luo C
Bioorg Med Chem Lett; 2018 May; 28(9):1476-1483. PubMed ID: 29628326
[TBL] [Abstract][Full Text] [Related]
13. Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion.
Wang M; Fuhrmann J; Thompson PR
Biochemistry; 2014 Dec; 53(50):7884-92. PubMed ID: 25485739
[TBL] [Abstract][Full Text] [Related]
14. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
Smith CR; Aranda R; Bobinski TP; Briere DM; Burns AC; Christensen JG; Clarine J; Engstrom LD; Gunn RJ; Ivetac A; Jean-Baptiste R; Ketcham JM; Kobayashi M; Kuehler J; Kulyk S; Lawson JD; Moya K; Olson P; Rahbaek L; Thomas NC; Wang X; Waters LM; Marx MA
J Med Chem; 2022 Feb; 65(3):1749-1766. PubMed ID: 35041419
[TBL] [Abstract][Full Text] [Related]
15. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy.
Zhou Z; Feng Z; Hu D; Yang P; Gur M; Bahar I; Cristofanilli M; Gradishar WJ; Xie XQ; Wan Y
EBioMedicine; 2019 Jun; 44():98-111. PubMed ID: 31101597
[TBL] [Abstract][Full Text] [Related]
16. Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Mao R; Shao J; Zhu K; Zhang Y; Ding H; Zhang C; Shi Z; Jiang H; Sun D; Duan W; Luo C
J Med Chem; 2017 Jul; 60(14):6289-6304. PubMed ID: 28650658
[TBL] [Abstract][Full Text] [Related]
17. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Wang Y; Hu W; Yuan Y
J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
Lin H; Luengo JI
Bioorg Med Chem Lett; 2019 Jun; 29(11):1264-1269. PubMed ID: 30956011
[TBL] [Abstract][Full Text] [Related]
19. Taming PRMT5-adaptor protein interactions.
Sims HS; Dai M
Trends Pharmacol Sci; 2023 Mar; 44(3):134-136. PubMed ID: 36669975
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations.
Tao H; Yan X; Zhu K; Zhang H
Chem Pharm Bull (Tokyo); 2019; 67(4):382-388. PubMed ID: 30930442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
